To select the nanovaccine with the strongest anti‐tumor effect against solid tumors and evaluate if the anti‐tumor effect is mediated by CD8+ T cells, MC38‐bearing mice were treated with two doses of PLGA‐PEG‐Man or PLGA‐POx‐Man nanovaccines (MHCI‐Adpgk NP/MHCII‐Adpgk NP), 7 days apart, with or without CD8+ T‐cell depletion (Figure 2Q). The gene discussed is CD8A; the disease is neoplasm.